Barchart on MSN2d
2 Growth Stocks to Buy Now With 367% to 410% UpsideBiotech companies make some of the best growth stocks. These firms are at the forefront of medical advances such as gene ...
MyChesCo on MSN2d
iECURE to Present Promising Initial Data from Gene Editing Trial for Neonatal OTC DeficiencyPHILADELPHIA, PA — iECURE, Inc. has announced that early data from its Phase 1/2 OTC-HOPE clinical trial, evaluating the gene ...
In a recent study published in Science Advances, researchers led by Prof. Li Xinjian from the Institute of Biophysics of the ...
Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...
Reports Q4 revenue $22.8M, consensus $44.64M. “We continue to progress our flagship rare disease programs and look forward to sharing ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
12d
Arcturus Therapeutics Holdings Inc. a publié ses résultats pour l'exercice clos le 31 décembre 2024. Pour l'ensemble de ...
Arcturus Therapeutics Holdings Inc. a publié ses résultats pour le quatrième trimestre clos le 31 décembre 2024. Pour le ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
By using a multitracer stable isotope design, we sought to determine the ability of the human neonate to synthesize arginine and its immediate biochemical precursors, citrulline and ornithine ...
Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, Michigan 49503, United States International Center for Polyamine Disorders, Grand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback